• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Combination therapy effective for patients receiving multiple and monotherapy glaucoma regimens

Article

A combination anti-glaucoma drug that includes brimonidine tartrate ophthalmic solution 0.2% and timolol ophthalmic solution 0.5% (Combigan, Allergan) has a significant impact on the IOP of most patients regardless of gender and whether they are undergoing multiple or monotherapy for glaucoma, said Saad Younis, MD, from West Middlesex University and Ashford Hospital, Middlesex, United Kingdom.

A combination anti-glaucoma drug that includes brimonidine tartrate ophthalmic solution 0.2% and timolol ophthalmic solution 0.5% (Combigan, Allergan) has a significant impact on the IOP of most patients regardless of gender and whether they are undergoing multiple or monotherapy for glaucoma, said Saad Younis, MD, from West Middlesex University and Ashford Hospital, Middlesex, United Kingdom.

"Patients requiring multiple ocular antihypertensive drugs to control IOP may benefit from fixed combinations that offer reduced exposure to the potentially toxic effects of the preservative benzalkonium chloride, removal of the risk of washout of the first instilled medication, and improved chances of patient compliance with the prescribed regimen," Dr. Younis explained.

Dr. Younis conducted this study to investigate the ocular hypotensive effect of the combination anti-glaucoma drug and evaluate the medication's effect on men and women. Glaucoma patients receiving treatment and exhibiting visual field or progressive IOP damage were included. Patients who needed a change in medication because of adverse events were excluded.

Nineteen women and 18 men were included (mean age of women, 68.5; mean age of men, 66.5 years). Twenty patients had been treated with monotherapy before they received the combination anti-glaucoma drug; 17 patients had been on multiple therapy regimens. The mean baseline IOP was 24.2 and 25.6 mm Hg in women and men, respectively. Eight patients left the study (five because of an allergic reaction to the combination anti-glaucoma drug and three because of insufficient IOP control). No systemic side effects developed.

Dr. Younis reported that the mean IOP reductions in all women were 4.13 ± 3.71 mm Hg and 5.23 ± 3.39 mm Hg, when patient withdrawals were excluded from analysis. The mean IOP decreases in all men were 4.06 ± 3.9 mm Hg and 5.21 ± 3.66 mm Hg when patient withdrawals were excluded. Overall the mean IOP reduction after the addition of the combination anti-glaucoma drug in all patients was 4.09 ± 3.75 mm Hg. When patient withdrawals were excluded the mean IOP in all patients was 5.22 ± 3.46 mm Hg.

"This study indicated that [the combination anti-glaucoma drug] has a clinically significant impact on the IOP of most patients whether male or female and whether they are on multiple or monotherapy for glaucoma," Dr. Younis said.

Related Videos
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.